176 related articles for article (PubMed ID: 31356877)
1. A tale of two TrkA inhibitor trials: same target, divergent results.
Walsh DA; Neogi T
Osteoarthritis Cartilage; 2019 Nov; 27(11):1575-1577. PubMed ID: 31356877
[No Abstract] [Full Text] [Related]
2. Response to: 'Role of nerve growth factor (NGF) and tropomyosin receptor kinase A (TrkA) in the pathogenesis of osteoarthritis. Might NGF be the link interwinding obesity and OA?' by Iannone et al.
Nwosu LN; Walsh DA
Ann Rheum Dis; 2015 Dec; 74(12):e71. PubMed ID: 26420578
[No Abstract] [Full Text] [Related]
3. Osteoarthritis in 2016: Anti-NGF treatments for pain - two steps forward, one step back?
Lane NE; Corr M
Nat Rev Rheumatol; 2017 Jan; 13(2):76-78. PubMed ID: 28119540
[No Abstract] [Full Text] [Related]
4. Role of nerve growth factor and tropomyosin receptor kinase A in the pathogenesis of osteoarthritis. Might nerve growth factor be the link interwinding obesity and osteoarthritis?
Iannone F; Perniola S; Lopalco G; Cantarini L; Lapadula G
Ann Rheum Dis; 2015 Dec; 74(12):e70. PubMed ID: 26386127
[No Abstract] [Full Text] [Related]
5. Blocking the tropomyosin receptor kinase A (TrkA) receptor inhibits pain behaviour in two rat models of osteoarthritis.
Nwosu LN; Mapp PI; Chapman V; Walsh DA
Ann Rheum Dis; 2016 Jun; 75(6):1246-54. PubMed ID: 26286016
[TBL] [Abstract][Full Text] [Related]
6. Tropomyosin-related kinase A (TrkA) inhibition for the treatment of painful knee osteoarthritis: results from a randomized controlled phase 2a trial.
Watt FE; Blauwet MB; Fakhoury A; Jacobs H; Smulders R; Lane NE
Osteoarthritis Cartilage; 2019 Nov; 27(11):1590-1598. PubMed ID: 31356878
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of intra-articular injection of tropomyosin receptor kinase A inhibitor in painful knee osteoarthritis: a randomized, double-blind and placebo-controlled study.
Krupka E; Jiang GL; Jan C
Osteoarthritis Cartilage; 2019 Nov; 27(11):1599-1607. PubMed ID: 31351965
[TBL] [Abstract][Full Text] [Related]
8. [The fine line between innovation and risk : Is anti-NGF a pain medication of the future?].
Schaible HG
Schmerz; 2010 Dec; 24(6):559-60. PubMed ID: 21057818
[No Abstract] [Full Text] [Related]
9. The Efficacy, Tolerability, and Joint Safety of Fasinumab in Osteoarthritis Pain: A Phase IIb/III Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
Dakin P; DiMartino SJ; Gao H; Maloney J; Kivitz AJ; Schnitzer TJ; Stahl N; Yancopoulos GD; Geba GP
Arthritis Rheumatol; 2019 Nov; 71(11):1824-1834. PubMed ID: 31207169
[TBL] [Abstract][Full Text] [Related]
10. Acetaminophen in Perspective.
Sulich A
J Am Geriatr Soc; 2016 Nov; 64(11):2397-2398. PubMed ID: 27626236
[No Abstract] [Full Text] [Related]
11. Towards a mechanism-based approach to pain management in osteoarthritis.
Malfait AM; Schnitzer TJ
Nat Rev Rheumatol; 2013 Nov; 9(11):654-64. PubMed ID: 24045707
[TBL] [Abstract][Full Text] [Related]
12. Targeting nerve growth factor in pain: what is the therapeutic potential?
Watson JJ; Allen SJ; Dawbarn D
BioDrugs; 2008; 22(6):349-59. PubMed ID: 18998753
[TBL] [Abstract][Full Text] [Related]
13. Structural, biological, and pharmacological strategies for the inhibition of nerve growth factor.
Eibl JK; Strasser BC; Ross GM
Neurochem Int; 2012 Dec; 61(8):1266-75. PubMed ID: 23103525
[TBL] [Abstract][Full Text] [Related]
14. Osteoarthritis in 2010: New takes on treatment and prevention.
Felson DT
Nat Rev Rheumatol; 2011 Feb; 7(2):75-6. PubMed ID: 21289610
[No Abstract] [Full Text] [Related]
15. Pain characteristics and biomarkers in treatment approaches for osteoarthritis pain.
Fayet M; Hagen M
Pain Manag; 2021 Jan; 11(1):59-73. PubMed ID: 33124514
[TBL] [Abstract][Full Text] [Related]
16. Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial.
Brown MT; Murphy FT; Radin DM; Davignon I; Smith MD; West CR
Arthritis Rheum; 2013 Jul; 65(7):1795-803. PubMed ID: 23553790
[TBL] [Abstract][Full Text] [Related]
17. Information from your family doctor. Osteoarthritis: how to stay active.
Am Fam Physician; 2004 Mar; 69(5):1211-2. PubMed ID: 15023027
[No Abstract] [Full Text] [Related]
18. Adalimumab in patients with hand osteoarthritis refractory to analgesics and NSAIDs: a randomised, multicentre, double-blind, placebo-controlled trial.
Chevalier X; Ravaud P; Maheu E; Baron G; Rialland A; Vergnaud P; Roux C; Maugars Y; Mulleman D; Lukas C; Wendling D; Lafforgue P; Loeuille D; Foltz V; Richette P;
Ann Rheum Dis; 2015 Sep; 74(9):1697-705. PubMed ID: 24817417
[TBL] [Abstract][Full Text] [Related]
19. Development of a pharmacodynamic biomarker to measure target engagement from inhibition of the NGF-TrkA pathway.
Price EA; Krasowska-Zoladek A; Nanda KK; Stachel SJ; Henze DA
J Neurosci Methods; 2017 Apr; 282():34-42. PubMed ID: 28279735
[TBL] [Abstract][Full Text] [Related]
20. Pain: Could TRPV1-targeted analgesia of OA pain still be feasible?
Killock D
Nat Rev Rheumatol; 2013 Dec; 9(12):698. PubMed ID: 24217583
[No Abstract] [Full Text] [Related]
[Next] [New Search]
